Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program

被引：0
|
作者：
Vermeire, Severine [1 ]
Rubin, David T. [2 ]
Peyrin-Biroulet, Laurent [3 ,4 ]
Dubinsky, Marla C. [5 ]
Regueiro, Miguel [6 ]
Irving, Peter M. [7 ]
Goetsch, Martina [8 ]
Lazin, Krisztina [8 ]
Wu, Joseph [9 ]
Modesto, Irene [10 ]
Woolcott, John C. [11 ]
McDonnell, Aoibhinn [12 ]
Rabbat, Christopher J. [10 ]
Yarur, Andres J. [13 ]
机构：
[1] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium
[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[3] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France
[4] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France
[5] Mt Sinai Kravis Childrens Hosp, New York, NY USA
[6] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH USA
[7] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England
[8] Pfizer AG, Zurich, Switzerland
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Inc, New York, NY USA
[11] Pfizer Inc, Collegeville, PA USA
[12] Pfizer Ltd, Sandwich, Kent, England
[13] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S905
引用
收藏
页码：S675 / S675
页数：1
相关论文
共 50 条
  • [1] Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program
    Regueiro, Miguel
    Vermeire, Severine
    Rubin, David T.
    Dubinsky, Marla C.
    Hart, Ailsa
    Wu, Joseph
    Green, Jesse
    Woolcott, John C.
    Gorelick, Kenneth J.
    McDonnell, Aoibhinn
    Lazin, Krisztina
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S817
  • [2] Etrasimod for ulcerative colitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (05): : 405 - 405
  • [3] Etrasimod for ulcerative colitis
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 708 - 708
  • [4] Etrasimod (Velsipity) for Ulcerative Colitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1690): : 187 - 189
  • [5] Etrasimod for the treatment of ulcerative colitis
    Wils, Pauline
    Peyrin-Biroulet, Laurent
    IMMUNOTHERAPY, 2023, 15 (05) : 311 - 321
  • [6] Ulcerative colitis Etrasimod approved from the Age of 16
    Warpakowski, Andrea
    VISCERAL MEDICINE, 2024, 40 (03)
  • [7] Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
    Lichtenstein, Gary R.
    Allegretti, Jessica R.
    Loftus Jr, Edward, V
    Irving, Peter M.
    Banerjee, Rupa
    Charabaty, Aline
    Kuehbacher, Tanja
    Bananis, Eustratios
    Woolcott, John C.
    Dalam, Alexis B.
    Lazin, Krisztina
    Keating, Michael
    Mcdonnell, Aoibhinn
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2025,
  • [8] Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme
    Vermeire, S.
    Rubin, D. T.
    Regueiro, M. D.
    Takeuchi, K.
    Walsh, A.
    Kotze, P. G.
    Charabaty, A.
    Goetsch, M.
    Lazin, K.
    Wu, J.
    Tsamos, G.
    Segovia, M.
    Branquinho, D.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i115 - i117
  • [9] Etrasimod for ulcerative colitis: evaluating phase III results
    Matsuoka, Katsuyoshi
    Hibi, Toshifumi
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (12) : 762 - 763
  • [10] Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
    Vermeire, S.
    Peyrin-Biroulet, L.
    Panes, J.
    Regueiro, M.
    Kotze, P. G.
    Charabaty, A.
    Goetsch, M.
    Shan, K.
    Wu, J.
    McDonnell, A.
    Woolcott, J.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 619 - 619
12345